Antiangiogenic effect of erythromycin: An in vitro model of Bartonella quintana infection

Journal of Infectious Diseases

Volumn 193, Issue 3, 2006, Pages 380-386

  Meghari, Soraya ^a   Rolain, Jean Marc ^a   Grau, Georges E ^a   Platt, Esther ^a   Barrassi, Lina ^a   Mège, Jean Louis ^a   Raoult, Didier ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; RIBOSOMAL PROTEIN L4; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM CULTURE; BARTONELLA QUINTANA; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENDOTHELIUM CELL; GENE INSERTION; GENETIC CONSERVATION; HEMANGIOMATOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RICKETTSIOSIS; WILD TYPE;

AMINO ACID SEQUENCE; ANGIOMATOSIS, BACILLARY; ANTI-BACTERIAL AGENTS; BARTONELLA QUINTANA; CELL PROLIFERATION; DRUG RESISTANCE, BACTERIAL; ENDOTHELIAL CELLS; ERYTHROMYCIN; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 31044439808     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/499276     Document Type: Article

References (38)

1. Relman DA, Loutit JS, Schmidt TM, Falkow S, Tompkins LS. The agent of bacillary angiomatosis: an approach to the identification of uncultured pathogens. N Engl J Med 1990; 323:1573-80.
2. Relman DA, Falkow S, LeBoit PE, et al. The organism causing bacillary angiomatosis, peliosis hepatis, and fever and bacteremia in immunocompromised patients [letter]. N Engl J Med 1991; 324:1514.
3. Koehler JE, Quinn FD, Berger TG, LeBoit PE, Tappero JW. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 1992; 327:1625-31.
4. Kirby JE. In vitro model of Bartonella henselae-induced angiogenesis. Infect Immun 2004; 72:7315-7.
5. Dehio C. Bartonella interactions with endothelial cells and erythrocytes. Trends Microbiol 2001; 9:279-85.
6. Kirby JE, Nekorchuk DM. Bartonella-associated endothelial proliferation depends on inhibition of apoptosis. Proc Natl Acad Sci USA 2002; 99:4656-61.
7. Kempf VA, Volkmann B, Schaller M, et al. Evidence of a leading role for VEGF in Bartonella henselae-induced endothelial cell proliferations. Cell Microbiol 2001; 3:623-32.
8. Resto-Ruiz SI, Schmiederer M, Sweger D, et al. Induction of a potential paracrine angiogenic loop between human THP-1 macrophages and human microvascular endothelial cells during Bartonella henselae infection. Infect Immun 2002; 70:4564-70.
9. Maurin M, Gasquet S, Ducco C, Raoult D. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother 1995; 39:2387-91.
10. Stoler MH, Bonfiglio TA, Steigbigel RT, Pereira M. An atypical subcutaneous infection associated with acquired immune deficiency syndrome. Am J Clin Pathol 1983; 80:714-8.
11. Koehler JE, Sanchez MA, Garrido CS, et al. Molecular epidemiology of bartonella infections in patients with bacillary angiomatosis-peliosis. N Engl J Med 1997; 337:1876-83.
12. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921-33.
13. Yatsunami J, Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res 2001; 21:4253-8.
14. Wolfson C, Branley J, Gottlieb T. The Etest for antimicrobial susceptibility testing of Bartonella henselae. J Antimicrob Chemother 1996; 38:963-8.
15. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001; 45:1-12.
16. Rolain JM, Arnoux D, Parzy D, Sampol J, Raoult D. Experimental infection of human erythrocytes from alcoholic patients with Bartonella quintana. Ann NY Acad Sci 2003; 990:605-11.
17. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99:683-90.
18. Brouqui P, Raoult D. Bartonella quintana invades and multiplies within endothelial cells in vitro and in vivo and forms intracellular blebs. Res Microbiol 1996; 147:719-31.
19. Teysseire N, Boudier JA, Raoult D. Rickettsia conorii entry into Vero cells. Infect Immun 1995; 63:366-74.
20. Batterman HJ, Peek JA, Loutit JS, Falkow S, Tompkins LS. Bartonella henselae and Bartonella quintana adherence to and entry into cultured human epithelial cells. Infect Immun 1995; 63:4553-6.
21. Riess T, Andersson SG, Lupas A, et al. Bartonella adhesin A mediates a proangiogenic host cell response. J Exp Med 2004; 200:1267-78.
22. Chittum HS, Champney WS. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol 1995; 30:273-9.
23. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000; 44:2118-25.
24. Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395-401.
25. Maurin M, Raoult D. Bartonella (Rochalimaea) quintana infections. Clin Microbiol Rev 1996; 9:273-92.
26. Coles WH. Effects of antibiotics on the in vitro rabbit corneal endothelium. Invest Ophthalmol 1975; 14:246-50.
27. Lanbeck P, Paulsen O. Cytotoxic effects of four antibiotics on endothelial cells. Pharmacol Toxicol 1995; 77:365-70.
28. Yatsunami J, Turuta N, Wakamatsu K, Hara N, Hayashi S. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. Res Exp Med (Berl) 1997; 197:189-97.
29. Yatsunami J, Tsuruta N, Fukuno Y, Kawashima M, Taniguchi S, Hayashi S. Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells. Clin Exp Metastasis 1999; 17:119-24.
30. Yatsunami J, Tsuruta N, Hara N, Hayashi S. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998; 131:137-43.
31. Enomoto F, Kin R, Kataoka T, et al. Modulation of neutrophil adhesion to vascular endothelial cells in rat experimental otitis media treated with a macrolide. Auris Nasus Larynx 2003; 30:247-51.
32. Akamatsu H, Yamawaki M, Horio T. Effects of roxithromycin on adhesion molecules expressed on endothelial cells of the dermal microvasculature. J Int Med Res 2001; 29:523-7.
33. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-303.
34. Hammerschlag MR. Effect of azithromycin on endothelial function of patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 106:e65-6.
35. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 2004; 71:1-9.
36. Jablonowski H, Fatkenheuer G, Youle M, Newell T, Lines S, Craft JC. Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients. Drugs 1997; 54(Suppl 2):16-22; discussion 28-9.
37. Pereyre S, Guyot C, Renaudin H, Charron A, Bebear C, Bebear CM. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. Antimicrob Agents Chemother 2004; 48:460-5.
38. Zhang P, Chomel BB, Schau MK, et al. A family of variably expressed outer-membrane proteins (Vomp) mediates adhesion and autoaggregation in Bartonella quintana. Proc Natl Acad Sci USA 2004; 101:13630-5.